Modulight Spotlights: LASER-SHARP RESEARCH – March 2025
Bladder cancer is the fourth most common cancer in men, and despite good prognosis, recurrences are very common with standard therapies. In a new publication by Jonathan Coleman and the group at the Memorial Sloan Kettering Cancer Center, vascular-targeted therapy was studied for bladder cancer as a minimally invasive treatment option. The therapy involves a photosensitive drug, padeliporfin, which binds to blood albumin and accumulates to tumor vasculature. When the bladder was illuminated with the Modulight’s ML7710 laser, it resulted in selective ablation of bladder tumors, without long-lasting effects on healthy bladder tissue. The therapy was also shown to enhance immune response against the tumor, which could enable long-term tumor control. Results show promise of vascular-targeted therapy also for the lower urinary tract, in addition to already clinically studied upper-tract urinary carcinoma.
Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!
#Laser-Sharp Research #BladderCancer #immuneresponse #padeliporfin #immuneactivation #immunotherapy
About Modulight’s LASER-SHARP RESEARCH concept:
Laser-Sharp Research is a concept where our scientific board highlights cutting-edge scientific research articles from our customers. Important selection criteria are that Modulight and laser product are mentioned in the publication, the impact and relevance of the results, clinical translatability, as well as scientific quality of the journal. The nominated research groups will be rewarded to encourage the great work done.
Contact Us
Do you have questions or comments related to this LASER-SHARP RESEARCH nomination? Maybe your group has done significant research that your would like us to spotlight? Or would you like to request literature? Please drop us a line!